Information Provided By: 
Fly News Breaks for January 23, 2019
LJPC
Jan 23, 2019 | 08:39 EDT
JPMorgan analyst Anupam Rama upgraded La Jolla Pharmaceutical to Neutral from Underweight while cutting his price target for the shares to $9 from $18. The analyst expects the focus to shift away from the Giapreza U.S. launch to other clinical programs, in particular the LJPC-401 program. He believes the shares shares will be more range bound in the first half of 2019, which forms his Neutral rating.
News For LJPC From the Last 2 Days
There are no results for your query LJPC
